Celltrion plans a KRW 1.2 trillion expansion at its Songdo headquarters, adding 180,000L of Drug Substance (DS) capacity with new Plants 4 and 5. This investment, extending through 2030, aims to increase total DS capacity to 571,000L, supporting pipeline products and its CMO business. The company is also expanding Drug Product (DP) manufacturing in Songdo and Yesan, targeting 90% DP supply internalization.
This substantial investment in manufacturing capacity positions Celltrion to meet growing global demand for its biologics and biosimilars, enhance its CMO business, and achieve greater cost efficiencies. The expansion aims to secure 100% internalization of DS production by 2031 and 90% of DP supply, bolstering its competitive edge and supply chain stability in the biopharmaceutical market.
KRW 1.2 trillion investment in Songdo for new DS production facilities.
Total DS capacity to reach 571,000L, with 100% internalization goal by 2031.
Expansion of DP manufacturing facilities targeting 90% internalization.
The expansion focuses on domestic facilities in Songdo and Yesan, South Korea, and the U.S. manufacturing site in Branchburg, New Jersey. This multi-regional approach aims to strengthen global manufacturing competitiveness, ensure supply stability, and mitigate trade risks.
Expansion of DP manufacturing facilities targeting 90% internalization.
Investment supports pipeline products, CMO business, and cost competitiveness.
Sign in to save notes on signals.
Sign In